Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation. [GOC:BHF, GOC:mah]
Negative regulation of eosinophil extravasation is a complex process that involves a series of coordinated steps to prevent the excessive accumulation of eosinophils in tissues. Eosinophils are a type of white blood cell that play a crucial role in immune responses, particularly against parasitic infections. However, their uncontrolled recruitment can contribute to tissue damage in allergic reactions and inflammatory diseases.
The process of negative regulation of eosinophil extravasation involves several key steps:
**1. Inhibition of Eosinophil Adhesion:**
- Adhesion molecules, such as ICAM-1 and VCAM-1, on endothelial cells play a crucial role in eosinophil recruitment.
- Negative regulation can involve downregulation of these adhesion molecules or the production of soluble adhesion molecule inhibitors.
- For example, the cytokine IL-10 can suppress ICAM-1 expression, reducing eosinophil adhesion.
**2. Blockade of Chemotaxis:**
- Chemokines, such as eotaxin, attract eosinophils to the site of inflammation.
- Negative regulation can involve blocking the production of these chemokines or inhibiting their signaling pathways.
- For instance, corticosteroids can suppress eotaxin production, reducing chemotaxis.
**3. Inhibition of Eosinophil Activation:**
- Eosinophils become activated upon encountering inflammatory stimuli, releasing cytotoxic mediators that can damage tissues.
- Negative regulation can involve inhibiting the activation signals or blocking the release of these mediators.
- For example, the cytokine IL-10 can suppress eosinophil activation and prevent the release of toxic mediators.
**4. Induction of Eosinophil Apoptosis:**
- Eosinophils have a limited lifespan, and programmed cell death (apoptosis) is a crucial mechanism for their removal from tissues.
- Negative regulation can involve inducing apoptosis in eosinophils, preventing their accumulation and potential damage.
- For example, glucocorticoids can induce eosinophil apoptosis.
**5. Immunomodulatory Effects:**
- Some regulatory mechanisms involve shifting the immune response towards a less inflammatory profile.
- For example, the cytokine IL-10 can promote the differentiation of regulatory T cells, which suppress inflammatory responses.
In summary, negative regulation of eosinophil extravasation is a multi-faceted process that involves inhibiting eosinophil adhesion, blocking chemotaxis, inhibiting activation, inducing apoptosis, and modulating the immune response. These mechanisms are critical for preventing excessive inflammation and tissue damage in various conditions, including allergies, asthma, and parasitic infections.
'
"
Protein | Definition | Taxonomy |
---|---|---|
Prostaglandin E2 receptor EP4 subtype | [no definition available] | Canis lupus familiaris (dog) |
Prostaglandin E2 receptor EP4 subtype | A prostaglandin E2 receptor EP4 subtype that is encoded in the genome of human. [PRO:WCB, UniProtKB:P35408] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
metergoline | metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy. | carbamate ester; ergoline alkaloid | dopamine agonist; geroprotector; serotonergic antagonist |
ah 6809 | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid: structure given in UD | xanthones | |
dinoprostone | prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | prostaglandins E | human metabolite; mouse metabolite; oxytocic |
dinoprost | Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor. | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite |
butaprost | |||
cloprostenol | Cloprostenol: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle. | prostanoid | |
tg4-155 | TG4-155: an EP2 receptor antagonist; structure in first source | ||
mk-0524 | MK-0524: a potent orally active human prostaglandin D(2) receptor 1 antagonist; structure in first source | indolyl carboxylic acid | |
cp533536 | CP533536: an EP2 receptor-selective prostaglandin E2 agonist that induces bone healing; structure in first source | monocarboxylic acid | |
amg 009 | AMG 009: an anti-inflammatory agent; structure in first source | ||
dg 041 | |||
cj-042794 | aromatic ether | ||
gw9508 | GW9508: structure in first source | aromatic amine | |
cj-023,423 | grapiprant: a potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties; cyclooxygenase inhibitors | ||
l-798106 | L-798106 : An N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of o-naphthalen-2-ylcinnamic acid with the sulfonamide group of 5-bromo-2-methoxybenzenesulfonamide. It is a selective antagonist for the prostanoid receptor EP3, a prostaglandin receptor for prostaglandin E2 (PGE2). | aromatic ether; bromobenzenes; N-sulfonylcarboxamide | prostaglandin receptor antagonist |
cp 544326 | CP 544326: structure in first source | ||
fevipiprant | fevipiprant: a CRTh2 antagonist; structure in first source | ||
fr181157 | |||
pf-04418948 | 1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acid: structure in first source | ||
cay 10580 | 2-(3-hydroxyoctyl)-5-oxo-1-pyrrolidineheptanoic acid : A pyrrolidin-2-one substituted by 6-carboxyhexyl and 3-hydroxyoctyl groups at positions 1 and 2, respectively. It is a potent prostaglandin EP4 receptor agonist (Ki=35 nM). CAY 10580: a E-prostanoid EP4 receptor agonist | hydroxy monocarboxylic acid; pyrrolidin-2-ones; secondary alcohol | prostaglandin receptor agonist |
tg6-10-1 | TG6-10-1: brain-permeant prostaglandin E receptor 2 antagonist; structure in first source |